<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924609</url>
  </required_header>
  <id_info>
    <org_study_id>20160504</org_study_id>
    <nct_id>NCT03924609</nct_id>
  </id_info>
  <brief_title>Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients</brief_title>
  <official_title>Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients: A Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to retrospectively collect and analyse the characteristics of
      breast cancer patients with bone metastasis, and compare the impact of intensive follow-up
      with standard post-operative surveillance on survival of Chinese breast cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is one of the most common malignant tumors in women, and the incidence rate is
      gradually increasing, accounts for the first place in the incidence of female malignant
      tumors. Bone metastasis is the most common distant metastatic site for breast cancer,
      accounting for approximately 70% of all patients with advanced breast cancer. About 26%-50%
      of breast cancer patients with primary metastases are bone. Autopsy results showed that the
      overall incidence of breast cancer bone metastasis was about 47%-85%.

      Postoperative routine screening for bone metastases in breast cancer patients, whether
      domestic or foreign, is not recommended in most guidelines. These recommendations were based
      on two prospective randomized controlled trials in Italy in 1990s, indicated that a bone scan
      every six months or annually didn't provide a survival benefit to the patient. However, there
      were researches showing that about 11% of patients with asymptomatic breast cancer have bone
      metastases, suggesting that early screening might detect more patients with asymptomatic bone
      metastases. The meta-analysis also pointed out that early screening may prolong the
      disease-free survival of patients. Besides, the imaging techniques have advance rapidly and
      remarkably since then. New trials are needed to figure out whether imaging screening of
      asymptomatic patients should be routinely performed to detect more asymptomatic bone
      metastases needs further investigation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months, and bone scan is repeated every 12 months</time_frame>
    <description>defined as the period from randomization to death from any cause, and it is censored at the last follow-up date when the patient is alive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>60 months, and bone scan is repeated every 12 months</time_frame>
    <description>defined as time to disease recurrence (invasive local, regional, or distant metastasis) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>60 months, and bone scan is repeated every 12 months</time_frame>
    <description>defined as time to distant metastasis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Bone metastasis screening</arm_group_label>
    <description>The information about bone metastasis screening is retrospectively collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Intensive screening / routine screening</intervention_name>
    <description>Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.</description>
    <arm_group_label>Bone metastasis screening</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1500 breast cancer patients with bone metastasis diagnosed between 2006 and 2011
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Histologically proven breast cancer confirmed by biopsy or pathological examination of
        the resected tumor.

        B. Histologically confirmed breast cancer patients, fulfilling any of the following:

          1. . Multiple bone metastases indicated by bone scan

          2. . Bone scan positive, and proven by other imaging examinations, including computed
             tomography (CT), magnetic resonance imaging (MRI) and X-ray.

          3. . Bone scan positive, with clinical symptoms, including bone pain, pathologic
             fracture, spinal cord compression and so on.

          4. . Bone metastases indicated by PET-CT

          5. . Histologically proven bone metastases

        Exclusion Criteria:

        A. No bone metastases confirmed by pathological examination B. Bone metastases secondary to
        other malignant tumor other than breast cancer C. Secondary primary tumor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Shu Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994 May 25;271(20):1593-7.</citation>
    <PMID>7848404</PMID>
  </reference>
  <reference>
    <citation>Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994 May 25;271(20):1587-92.</citation>
    <PMID>8182811</PMID>
  </reference>
  <reference>
    <citation>Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini P. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999 May 5;281(17):1586.</citation>
    <PMID>10235147</PMID>
  </reference>
  <reference>
    <citation>Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli TM, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001768. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD001768.</citation>
    <PMID>15674884</PMID>
  </reference>
  <reference>
    <citation>Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar;14(3):324-54.</citation>
    <PMID>26957618</PMID>
  </reference>
  <reference>
    <citation>Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE; American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1;31(7):961-5. doi: 10.1200/JCO.2012.45.9859. Epub 2012 Nov 5. Review.</citation>
    <PMID>23129741</PMID>
  </reference>
  <reference>
    <citation>Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011 Sep;129(2):495-503. doi: 10.1007/s10549-011-1475-5. Epub 2011 Apr 2.</citation>
    <PMID>21461730</PMID>
  </reference>
  <reference>
    <citation>Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep. 2017 Mar 27;7:45411. doi: 10.1038/srep45411.</citation>
    <PMID>28345619</PMID>
  </reference>
  <reference>
    <citation>Xiong Z, Deng G, Huang X, Li X, Xie X, Wang J, Shuang Z, Wang X. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res. 2018 Feb 9;10:287-295. doi: 10.2147/CMAR.S155524. eCollection 2018.</citation>
    <PMID>29467583</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Zhu W, Biskup E, Yang W, Yang Z, Wang H, Qiu X, Zhang C, Hu G, Hu G. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data. J Bone Oncol. 2018 Feb 3;11:38-50. doi: 10.1016/j.jbo.2018.01.004. eCollection 2018 Jun. Review.</citation>
    <PMID>29511626</PMID>
  </reference>
  <reference>
    <citation>Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013 Feb;24(2):398-405. doi: 10.1093/annonc/mds277. Epub 2012 Oct 9.</citation>
    <PMID>23047045</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>April 21, 2019</last_update_submitted>
  <last_update_submitted_qc>April 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

